

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
21 July 2005 (21.07.2005)

PCT

(10) International Publication Number
WO 2005/066128 A1

(51) International Patent Classification⁷: A61K 31/445, A61P 25/04, 25/22

C07D 211/70,

(74) Agent: ASTRAZENECA; Global Intellectual Property, S-151 85 Södertälje (SE).

(21) International Application Number: PCT/SE2005/000013

(22) International Filing Date: 5 January 2005 (05.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 0400025-3 9 January 2004 (09.01.2004) SE

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **BROWN, William** [CA/CA]; AstraZeneca R & D Montreal, 7171 Fredrick-Banting, Ville St. Laurent, Montreal, Québec H4S 1Z9 (CA). **GRiffin, Andrew** [GB/CA]; AstraZeneca R & D Montreal, 7171 Fredrick-Banting, Ville St. Laurent, Montreal, Québec H4S 1Z9 (CA). **WALPOLE, Christopher** [GB/CA]; AstraZeneca R & D Montreal, 7171 Fredrick-Banting, Ville St. Laurent, Montreal, Québec H4S 1Z9 (CA).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DIARYLMETHYLDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF



(57) Abstract: Compounds of Formula: wherein R¹, R², and R³ are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

**DIARYLMETHYLDENE PIPERIDINE DERIVATIVES, PREPARATIONS
THEREOF AND USES THEREOF**

FIELD OF THE INVENTION

5 The present invention is directed to novel compounds, to a process for their preparation, their use and pharmaceutical compositions comprising the novel compounds. The novel compounds are useful in therapy, and in particular for the treatment of pain, anxiety and functional gastrointestinal disorders.

10 BACKGROUND OF THE INVENTION

 The δ receptor has been identified as having a role in many bodily functions such as circulatory and pain systems. Ligands for the δ receptor may therefore find potential use as analgesics, and/or as antihypertensive agents. Ligands for the δ receptor have also been shown to possess immunomodulatory activities.

15 The identification of at least three different populations of opioid receptors (μ , δ and κ) is now well established and all three are apparent in both central and peripheral nervous systems of many species including man. Analgesia has been observed in various animal models when one or more of these receptors has been activated.

20 With few exceptions, currently available selective opioid δ ligands are peptidic in nature and are unsuitable for administration by systemic routes. One example of a non-peptidic δ -agonist is SNC80 (Bilsky E.J. et al., Journal of Pharmacology and Experimental Therapeutics, 273(1), pp. 359-366 (1995)).

25 Many δ agonist compounds that have been identified in the prior art have many disadvantages in that they suffer from poor pharmacokinetics and are not analgesic when administered by systemic routes. Also, it has been documented that many of these δ agonist compounds show significant convulsive effects when administered systemically.

 U.S. Patent No. 6,187,792 to Delorme et al. describes some δ -agonists. 30 However, there is still a need for improved δ -agonists.

DESCRIPTION OF THE INVENTION

Unless specified otherwise within this specification, the nomenclature used in this specification generally follows the examples and rules stated in *Nomenclature of Organic Chemistry, Sections A, B, C, D, E, F, and H*, Pergamon Press, Oxford, 1979,

5 which is incorporated by reference herein for its exemplary chemical structure names and rules on naming chemical structures.

The term "C_{m-n}" or "C_{m-n} group" used alone or as a prefix, refers to any group having m to n carbon atoms.

10 The term "hydrocarbon" used alone or as a suffix or prefix, refers to any structure comprising only carbon and hydrogen atoms up to 14 carbon atoms.

The term "hydrocarbon radical" or "hydrocarbyl" used alone or as a suffix or prefix, refers to any structure as a result of removing one or more hydrogens from a hydrocarbon.

15 The term "alkyl" used alone or as a suffix or prefix, refers to a saturated monovalent straight or branched chain hydrocarbon radical comprising 1 to about 12 carbon atoms. Illustrative examples of alkyls include, but are not limited to, C₁₋₆alkyl groups, such as methyl, ethyl, propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, and hexyl, and longer alkyl groups, such as heptyl, and octyl. An alkyl can be unsubstituted or substituted with one or two suitable substituents.

25 The term "alkylene" used alone or as suffix or prefix, refers to divalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms, which serve to link two structures together.

30 The term "alkenyl" used alone or as suffix or prefix, refers to a monovalent straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond and comprising at least 2 up to about 12 carbon atoms. The double bond of an alkenyl can be unconjugated or conjugated to another unsaturated group.

Suitable alkenyl groups include, but are not limited to C₂₋₆alkenyl groups, such as vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-

ethylhexenyl, 2-propyl-2-butenyl, 4-(2-methyl-3-butene)-pentenyl. An alkenyl can be unsubstituted or substituted with one or two suitable substituents.

The term “alkynyl” used alone or as suffix or prefix, refers to a monovalent straight or branched chain hydrocarbon radical having at least one carbon-carbon

5 triple bond and comprising at least 2 up to about 12 carbon atoms. The triple bond of an alkynyl group can be unconjugated or conjugated to another unsaturated group. Suitable alkynyl groups include, but are not limited to, C_{2-6} alkynyl groups, such as ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, 4-methyl-1-butynyl, 4-propyl-2-pentynyl, and 4-butyl-2-hexynyl. An alkynyl can be unsubstituted or

10 substituted with one or two suitable substituents.

The term “cycloalkyl,” used alone or as suffix or prefix, refers to a saturated monovalent ring-containing hydrocarbon radical comprising at least 3 up to about 12 carbon atoms. Examples of cycloalkyls include, but are not limited to, C_{3-7} cycloalkyl groups, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl,

15 and saturated cyclic and bicyclic terpenes. A cycloalkyl can be unsubstituted or substituted by one or two suitable substituents. Preferably, the cycloalkyl is a monocyclic ring or bicyclic ring.

The term “cycloalkenyl” used alone or as suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical having at least one carbon-carbon

20 double bond and comprising at least 3 up to about 12 carbon atoms.

The term “cycloalkynyl” used alone or as suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical having at least one carbon-carbon triple bond and comprising about 7 up to about 12 carbon atoms.

The term “aryl” used alone or as suffix or prefix, refers to a monovalent hydrocarbon radical having one or more polyunsaturated carbon rings having aromatic character, (e.g., $4n + 2$ delocalized electrons) and comprising 5 up to about

25 14 carbon atoms.

The term “arylene” used alone or as suffix or prefix, refers to a divalent hydrocarbon radical having one or more polyunsaturated carbon rings having aromatic character, (e.g., $4n + 2$ delocalized electrons) and comprising 5 up to about

30 14 carbon atoms, which serves to link two structures together.

The term "heterocycle" used alone or as a suffix or prefix, refers to a ring-containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s). Heterocycle may be

5 saturated or unsaturated, containing one or more double bonds, and heterocycle may contain more than one ring. When a heterocycle contains more than one ring, the rings may be fused or unfused. Fused rings generally refer to at least two rings share two atoms therebetween. Heterocycle may have aromatic character or may not have aromatic character.

10 The term "heteroaromatic" used alone or as a suffix or prefix, refers to a ring-containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s), wherein the ring-containing structure or molecule has an aromatic character (*e.g.*, $4n + 2$ delocalized electrons).

15 The term "heterocyclic group," "heterocyclic moiety," "heterocyclic," or "heterocyclo" used alone or as a suffix or prefix, refers to a radical derived from a heterocycle by removing one or more hydrogens therefrom.

20 The term "heterocyclyl" used alone or as a suffix or prefix, refers a monovalent radical derived from a heterocycle by removing one hydrogen therefrom.

The term "heterocyclene" used alone or as a suffix or prefix, refers to a divalent radical derived from a heterocycle by removing two hydrogens therefrom, which serves to links two structures together.

25 The term "heteroaryl" used alone or as a suffix or prefix, refers to a heterocyclyl having aromatic character.

The term "heterocylcoalkyl" used alone or as a suffix or prefix, refers to a monocyclic or polycyclic ring comprising carbon and hydrogen atoms and at least one heteroatom, preferably, 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulfur, and having no unsaturation. Examples of heterocycloalkyl groups include

30 pyrrolidinyl, pyrrolidino, piperidinyl, piperidino, piperazinyl, piperazino, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, and pyranyl. A heterocycloalkyl group can be unsubstituted or substituted with one or two suitable

substituents. Preferably, the heterocycloalkyl group is a monocyclic or bicyclic ring, more preferably, a monocyclic ring, wherein the ring comprises from 3 to 6 carbon atoms and form 1 to 3 heteroatoms, referred to herein as C₃₋₆heterocycloalkyl.

5 The term "heteroarylene" used alone or as a suffix or prefix, refers to a heterocyclylene having aromatic character.

The term "heterocycloalkylene" used alone or as a suffix or prefix, refers to a heterocyclylene that does not have aromatic character.

The term "six-membered" used as prefix refers to a group having a ring that contains six ring atoms.

10 The term "five-membered" used as prefix refers to a group having a ring that contains five ring atoms.

A five-membered ring heteroaryl is a heteroaryl with a ring having five ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.

15 Exemplary five-membered ring heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4-oxadiazolyl.

A six-membered ring heteroaryl is a heteroaryl with a ring having six ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.

20 Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.

The term "substituted" used as a prefix refers to a structure, molecule or group, wherein one or more hydrogens are replaced with one or more C₁₋₆hydrocarbon groups, or one or more chemical groups containing one or more heteroatoms selected from N, O, S, F, Cl, Br, I, and P. Exemplary chemical groups containing one or more heteroatoms include -NO₂, -OR, -Cl, -Br, -I, -F, -CF₃, -C(=O)R, -C(=O)OH, -NH₂, -SH, -NHR, -NR₂, -SR, -SO₃H, -SO₂R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR₂, -NRC(=O)R, oxo (=O), imino (=NR), thio (=S), and oximino (=N-OR), wherein each "R" is a C₁₋₆hydrocarbyl. For example, substituted phenyl may refer to nitrophenyl, methoxyphenyl, chlorophenyl, aminophenyl, etc., wherein the nitro, methoxy, chloro, and amino groups may replace any suitable hydrogen on the phenyl ring.

The term “substituted” used as a suffix of a first structure, molecule or group, followed by one or more names of chemical groups refers to a second structure, molecule or group, which is a result of replacing one or more hydrogens of the first structure, molecule or group with the one or more named chemical groups. For 5 example, a “phenyl substituted by nitro” refers to nitrophenyl.

Heterocycle includes, for example, monocyclic heterocycles such as: aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, pyrazoline, dioxolane, sulfolane 2,3-dihydrofuran, 2,5-dihydrofuran tetrahydrofuran, thiophane, piperidine, 1,2,3,6-tetrahydro-pyridine, 10 piperazine, morpholine, thiomorpholine, pyran, thiopyran, 2,3-dihydropyran, tetrahydropyran, 1,4-dihydropyridine, 1,4-dioxane, 1,3-dioxane, dioxane, homopiperidine, 2,3,4,7-tetrahydro-1*H*-azepine homopiperazine, 1,3-dioxepane, 4,7-dihydro-1,3-dioxepin, and hexamethylene oxide.

In addition, heterocycle includes aromatic heterocycles, for example, pyridine, 15 pyrazine, pyrimidine, pyridazine, thiophene, furan, furazan, pyrrole, imidazole, thiazole, oxazole, pyrazole, isothiazole, isoxazole, 1,2,3-triazole, tetrazole, 1,2,3-thiadiazole, 1,2,3-oxadiazole, 1,2,4-triazole, 1,2,4-thiadiazole, 1,2,4-oxadiazole, 1,3,4-triazole, 1,3,4-thiadiazole, and 1,3,4- oxadiazole.

Additionally, heterocycle encompass polycyclic heterocycles, for example, 20 indole, indoline, isoindoline, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, 1,4-benzodioxan, coumarin, dihydrocoumarin, benzofuran, 2,3-dihydrobenzofuran, isobenzofuran, chromene, chroman, isochroman, xanthene, phenoxythiin, thianthrene, indolizine, isoindole, indazole, purine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, phenanthridine, 25 perimidine, phenanthroline, phenazine, phenothiazine, phenoxyazine, 1,2-benzisoxazole, benzothiophene, benzoxazole, benzthiazole, benzimidazole, benztriazole, thioxanthine, carbazole, carboline, acridine, pyrolizidine, and quinolizidine.

In addition to the polycyclic heterocycles described above, heterocycle 30 includes polycyclic heterocycles wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms

common to both rings. Examples of such bridged heterocycles include quinuclidine, diazabicyclo[2.2.1]heptane and 7-oxabicyclo[2.2.1]heptane.

Heterocyclyl includes, for example, monocyclic heterocyclyls, such as: aziridinyl, oxiranyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrrolinyl, 5 imidazolidinyl, pyrazolidinyl, pyrazolinyl, dioxolanyl, sulfolanyl, 2,3-dihydrofuranyl, 2,5-dihydrofuranyl, tetrahydrofuranyl, thiophanyl, piperidinyl, 1,2,3,6-tetrahydro-pyridinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, 2,3-dihydropyran, tetrahydropyran, 1,4-dihydropyridinyl, 1,4-dioxanyl, 1,3-dioxanyl, dioxanyl, homopiperidinyl, 2,3,4,7-tetrahydro-1*H*-azepinyl, homopiperazinyl, 1,3-dioxepanyl, 4,7-dihydro-1,3-dioxepinyl, and hexamethylene oxidyl.

In addition, heterocyclyl includes aromatic heterocyclyls or heteroaryl, for example, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, furyl, furazanyl, 15 pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4-oxadiazolyl.

Additionally, heterocyclyl encompasses polycyclic heterocyclyls (including both aromatic or non-aromatic), for example, indolyl, indolinyl, isoindolinyl, 20 quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, 1,4-benzodioxanyl, coumarinyl, dihydrocoumarinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, isobenzofuranyl, chromenyl, chromanyl, isochromanyl, xanthenyl, phenoxathiinyl, thianthrenyl, indolizinyl, isoindolyl, indazolyl, purinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, phenanthridinyl, perimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, 25 phenoxazinyl, 1,2-benzisoxazolyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benzimidazolyl, benztriazolyl, thioxanthinyl, carbazolyl, carbolinyl, acridinyl, pyrolizidinyl, and quinolizidinyl.

In addition to the polycyclic heterocyclyls described above, heterocyclyl includes polycyclic heterocyclyls wherein the ring fusion between two or more rings 30 includes more than one bond common to both rings and more than two atoms common to both rings. Examples of such bridged heterocycles include quinuclidinyl, diazabicyclo[2.2.1]heptyl; and 7-oxabicyclo[2.2.1]heptyl.

The term "alkoxy" used alone or as a suffix or prefix, refers to radicals of the general formula $-O-R$, wherein R is selected from a hydrocarbon radical. Exemplary alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, isobutoxy, cyclopropylmethoxy, allyloxy, and propargyloxy.


5 The term "amine" or "amino" used alone or as a suffix or prefix, refers to radicals of the general formula $-N(R)R'$, wherein R and R' are independently selected from hydrogen or a hydrocarbon radical.

Halogen includes fluorine, chlorine, bromine and iodine.

10 "Halogenated," used as a prefix of a group, means one or more hydrogens on the group is replaced with one or more halogens.

"RT" or "rt" means room temperature.

In one aspect, the invention provides a compound of formula I, a pharmaceutically acceptable salt thereof, diastereomers thereof, enantiomers thereof, and mixtures thereof:



15

wherein

R¹ is selected from C₆₋₁₀aryl and C₂₋₆heteroaryl, wherein said C₆₋₁₀aryl and C₂₋₆heteroaryl are optionally substituted with one or more groups selected from -R, -NO₂, -OR, -Cl, -Br, -I, -F, -CF₃, -C(=O)R, -C(=O)OH, -NH₂, -SH, -NHR, -NR₂, -SR, -SO₃H, -SO₂R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR₂, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or C₁₋₆alkyl;

R² is selected from C₁₋₃alkyl and hydrogen; and

25 R³ is selected from hydrogen, -C(=O)-R⁴, -S(=O)₂-R⁴, and -C(=O)-O-R⁴, wherein R⁴ is selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl and C₂₋₆alkynyl.

In one embodiment, the compounds of the present invention are represented by formula I, wherein R¹ is selected from phenyl; thiadiazolyl, pyridyl; thienyl; furyl; imidazolyl; triazolyl; pyrrolyl; thiazolyl; and N-oxido-pyridyl, wherein said R¹ is further optionally substituted with one or more groups selected from C₁₋₆alkyl, 5 halogenated C₁₋₆alkyl, -NO₂, -CF₃, C₁₋₆ alkoxy, chloro, fluoro, bromo, and iodo;

R² is selected from C₁₋₃alkyl and hydrogen; and

R³ is selected from hydrogen, -C(=O)-R⁴, -S(=O)₂-R⁴, and -C(=O)-O-R⁴, wherein R⁴ is C₁₋₆alkyl.

In another embodiment, the compounds of the present invention are

10 represented by formula I, wherein R¹ is selected from phenyl; pyridyl; thiadiazolyl and thiazolyl, wherein R¹ is further optionally substituted with one or more groups selected from C₁₋₆alkyl, halogenated C₁₋₆alkyl, -NO₂, -CF₃, C₁₋₆ alkoxy, chloro, fluoro, bromo, and iodo;

R² is hydrogen; and

15 R³ is selected from hydrogen, -C(=O)-R⁴, -S(=O)₂-R⁴, and -C(=O)-O-R⁴, wherein R⁴ is C₁₋₃alkyl.

In a further embodiment, the compounds of the present invention are represented by formula I, wherein R¹ is selected from phenyl; 2-fluorophenyl; 3-fluorophenyl; 4-fluorophenyl; 2-pyridyl; 3-pyridyl; 4-pyridyl; 1,2,3-thiadiazol-4-yl; 4-thiazolyl and 5-thiazolyl;

R² is hydrogen; and

R³ is selected from hydrogen, -C(=O)-CH₃, -S(=O)₂-CH₃, and -C(=O)-O-CH₃.

It will be understood that when compounds of the present invention contain one or more chiral centers, the compounds of the invention may exist in, and be 25 isolated as, enantiomeric or diastereomeric forms, or as a racemic mixture. The present invention includes any possible enantiomers, diastereomers, racemates or mixtures thereof, of a compound of Formula I. The optically active forms of the compound of the invention may be prepared, for example, by chiral chromatographic separation of a racemate, by synthesis from optically active starting materials or by 30 asymmetric synthesis based on the procedures described thereafter.

It will also be appreciated that certain compounds of the present invention may exist as geometrical isomers, for example E and Z isomers of alkenes. The present

invention includes any geometrical isomer of a compound of Formula I. It will further be understood that the present invention encompasses tautomers of the compounds of the formula I.

It will also be understood that certain compounds of the present invention may 5 exist in solvated, for example hydrated, as well as unsolvated forms. It will further be understood that the present invention encompasses all such solvated forms of the compounds of the formula I.

Within the scope of the invention are also salts of the compounds of the formula I. Generally, pharmaceutically acceptable salts of compounds of the present 10 invention may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound, for example an alkyl amine with a suitable acid, for example, HCl or acetic acid, to afford a physiologically acceptable anion. It may also be possible to make a corresponding alkali metal (such as sodium, potassium, or lithium) or an alkaline earth metal (such as a calcium) salt by treating a 15 compound of the present invention having a suitably acidic proton, such as a carboxylic acid or a phenol with one equivalent of an alkali metal or alkaline earth metal hydroxide or alkoxide (such as the ethoxide or methoxide), or a suitably basic organic amine (such as choline or meglumine) in an aqueous medium, followed by conventional purification techniques.

20 In one embodiment, the compound of formula I above may be converted to a pharmaceutically acceptable salt or solvate thereof, particularly, an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, methanesulphonate or *p*-toluenesulphonate.

25 The novel compounds of the present invention are useful in therapy, especially for the treatment of various pain conditions such as chronic pain, neuropathic pain, acute pain, cancer pain, pain caused by rheumatoid arthritis, migraine, visceral pain etc. This list should however not be interpreted as exhaustive.

30 Compounds of the invention are useful as immunomodulators, especially for autoimmune diseases, such as arthritis, for skin grafts, organ transplants and similar surgical needs, for collagen diseases, various allergies, for use as anti-tumour agents and anti viral agents.

Compounds of the invention are useful in disease states where degeneration or dysfunction of opioid receptors is present or implicated in that paradigm. This may involve the use of isotopically labelled versions of the compounds of the invention in diagnostic techniques and imaging applications such as positron emission tomography (PET).

Compounds of the invention are useful for the treatment of diarrhoea, depression, anxiety and stress-related disorders such as post-traumatic stress disorders, panic disorder, generalized anxiety disorder, social phobia, and obsessive compulsive disorder, urinary incontinence, premature ejaculation, various mental illnesses, cough, lung oedema, various gastro-intestinal disorders, e.g. constipation, functional gastrointestinal disorders such as Irritable Bowel Syndrome and Functional Dyspepsia, Parkinson's disease and other motor disorders, traumatic brain injury, stroke, cardioprotection following myocardial infarction, spinal injury and drug addiction, including the treatment of alcohol, nicotine, opioid and other drug abuse and for disorders of the sympathetic nervous system for example hypertension.

Compounds of the invention are useful as an analgesic agent for use during general anaesthesia and monitored anaesthesia care. Combinations of agents with different properties are often used to achieve a balance of effects needed to maintain the anaesthetic state (e.g. amnesia, analgesia, muscle relaxation and sedation).

Included in this combination are inhaled anaesthetics, hypnotics, anxiolytics, neuromuscular blockers and opioids.

Also within the scope of the invention is the use of any of the compounds according to the formula I above, for the manufacture of a medicament for the treatment of any of the conditions discussed above.

A further aspect of the invention is a method for the treatment of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the formula I above, is administered to a patient in need of such treatment.

Thus, the invention provides a compound of formula I, or pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.

In a further aspect, the present invention provides the use of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

In the context of the present specification, the term "therapy" also includes 5 "prophylaxis" unless there are specific indications to the contrary. The term "therapeutic" and "therapeutically" should be construed accordingly. The term "therapy" within the context of the present invention further encompasses to administer an effective amount of a compound of the present invention, to mitigate either a pre-existing disease state, acute or chronic, or a recurring condition. This 10 definition also encompasses prophylactic therapies for prevention of recurring conditions and continued therapy for chronic disorders.

The compounds of the present invention are useful in therapy, especially for the therapy of various pain conditions including, but not limited to: chronic pain, neuropathic pain, acute pain, back pain, cancer pain, and visceral pain.

15 In use for therapy in a warm-blooded animal such as a human, the compound of the invention may be administered in the form of a conventional pharmaceutical composition by any route including orally, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracically, intravenously, epidurally, intrathecally, intracerebroventricularly and by injection into the joints.

20 In one embodiment of the invention, the route of administration may be orally, intravenously or intramuscularly.

25 The dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level at the most appropriate for a particular patient.

For preparing pharmaceutical compositions from the compounds of this invention, inert, pharmaceutically acceptable carriers can be either solid and liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.

30 A solid carrier can be one or more substances, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or table disintegrating agents; it can also be an encapsulating material.

In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided compound of the invention, or the active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

5 For preparing suppository compositions, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized moulds and allowed to cool and solidify.

10 Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.

15 The term composition is also intended to include the formulation of the active component with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier which is thus in association with it. Similarly, cachets are included.

Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.

20 Liquid form compositions include solutions, suspensions, and emulsions. For example, sterile water or water propylene glycol solutions of the active compounds may be liquid preparations suitable for parenteral administration. Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.

25 Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.

30 Depending on the mode of administration, the pharmaceutical composition will preferably include from 0.05% to 99%w (per cent by weight), more preferably

from 0.10 to 50%w, of the compound of the invention, all percentages by weight being based on total composition.

A therapeutically effective amount for the practice of the present invention may be determined, by the use of known criteria including the age, weight and 5 response of the individual patient, and interpreted within the context of the disease which is being treated or which is being prevented, by one of ordinary skills in the art.

Within the scope of the invention is the use of any compound of formula I as defined above for the manufacture of a medicament.

Also within the scope of the invention is the use of any compound of formula I 10 for the manufacture of a medicament for the therapy of pain.

Additionally provided is the use of any compound according to Formula I for the manufacture of a medicament for the therapy of various pain conditions including, but not limited to: chronic pain, neuropathic pain, acute pain, back pain, cancer pain, and visceral pain.

15 A further aspect of the invention is a method for therapy of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the formula I above, is administered to a patient in need of such therapy.


20 Additionally, there is provided a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.

25 Particularly, there is provided a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier for therapy, more particularly for therapy of pain.


Further, there is provided a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier use in any of the conditions discussed above.

30 In a further aspect, the present invention provides a method of preparing a compound of formula I.

In one embodiment, the invention provides a process for preparing a compound of formula I, comprising:



5 reacting a compound of formula II with X-R³ or R³-O-R³:




wherein X is halogen;

10 R¹ is selected from C₆₋₁₀aryl and C₂₋₆heteroaryl, wherein said C₆₋₁₀aryl and C₂₋₆heteroaryl are optionally substituted with one or more groups selected from -R, -NO₂, -OR, -Cl, -Br, -I, -F, -CF₃, -C(=O)R, -C(=O)OH, -NH₂, -SH, -NHR, -NR₂, -SR, -SO₃H, -SO₂R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR₂, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or C₁₋₆alkyl;


15 R² is selected from C₁₋₃alkyl and hydrogen; and

R³ is selected from -C(=O)-R⁴, -S(=O)₂-R⁴, and -C(=O)-O-R⁴, wherein R⁴ is selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl and C₂₋₆alkynyl.

In another embodiment, the present invention provides a process for preparing a compound of formula I, comprising:



5 reacting a compound of formula III with R¹-CHO:




III

wherein R¹ is selected from C₆₋₁₀aryl and C₂₋₆heteroaryl, wherein said C₆₋₁₀aryl and C₂₋₆heteroaryl are optionally substituted with one or more groups selected from -R, -NO₂, -OR, -Cl, -Br, -I, -F, -CF₃, -C(=O)R, -C(=O)OH, -NH₂, -SH, -NHR, -NR₂, -SR, -SO₃H, -SO₂R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR₂, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or C₁₋₆alkyl;

R² is selected from C₁₋₃alkyl and hydrogen; and


15 R³ is selected from -C(=O)-R⁴, -S(=O)₂-R⁴, and -C(=O)-O-R⁴, wherein R⁴ is selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl and C₂₋₆alkynyl.

In a further embodiment, the present invention provides a process for preparing a compound of formula I, comprising:



reacting a compound of formula IV with a compound of formula V or esters thereof:

5




wherein R¹ is selected from C₆-10aryl and C₂-6heteroaryl, wherein said C₆-10aryl and C₂-6heteroaryl are optionally substituted with one or more groups selected from -

R^2 is selected from C_{1-3} alkyl and hydrogen; and


R^3 is selected from $-H$, $-C(=O)-R^4$, $-S(=O)_2-R^4$, and $-C(=O)-O-R^4$, wherein R^4 is selected from $-H$, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl.

Particularly, the compounds of the present invention and intermediates used for the preparation thereof can be prepared according to the synthetic routes as exemplified in Schemes 1-5.


Scheme 1



Scheme 2




Scheme 3




Compound 3: R¹=2-pyridinyl
 Compound 4: R¹=3-pyridinyl
 Compound 5: R¹=4-pyridinyl
 Compound 6: R¹=1,2,3-thiadiazol-4-yl
 Compound 7: R¹=5-thiazolyl
 Compound 8: R¹=4-thiazolyl
 Compound 11: R¹=2-fluorophenyl
 Compound 12: R¹=3-fluorophenyl
 Compound 13: R¹=4-fluorophenyl

20


Scheme 4



Scheme 5



5 Accordingly, the present invention provides a chemical intermediate of formula VI, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:

**VI**

wherein R^2 is selected from C_{1-3} alkyl and hydrogen;

R^3 is selected from hydrogen, $-C(=O)-R^4$, $-S(=O)_2-R^4$, and $-C(=O)-O-R^4$,

5 wherein R^4 is selected from $-H$, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl; and

R^5 is selected from hydrogen and $-C(=O)-O-C_{1-6}$ alkyl.

BIOLOGICAL EVALUATION

The compounds of the invention are found to be active towards δ receptors in
 10 warm-blooded animal, e.g., human. Particularly the compounds of the invention are found to be effective δ receptor ligands. *In vitro* assays, *infra*, demonstrate these surprising activities, especially with regard to agonists potency and efficacy as demonstrated in the rat brain functional assay and/or the human δ receptor functional assay. This feature may be related to in vivo activity and may not be linearly
 15 correlated with binding affinity. In these *in vitro* assays, a compound is tested for their activity toward δ receptors and IC_{50} is obtained to determine the selective activity for a particular compound towards δ receptors. In the current context, IC_{50} generally refers to the concentration of the compound at which 50% displacement of a standard radioactive δ receptor ligand has been observed.

20 The activities of the compound towards κ and μ receptors are also measured in a similar assay.

In vitro modelCell culture

Human 293S cells expressing cloned human κ , δ and μ receptors and neomycin resistance are grown in suspension at 37°C and 5% CO₂ in shaker flasks containing calcium-free DMEM10% FBS, 5% BCS, 0.1% Pluronic F-68, and 600 μ g/ml geneticin.

Rat brains are weighed and rinsed in ice-cold PBS (containing 2.5mM EDTA, pH 7.4). The brains are homogenized with a polytron for 30 sec (rat) in ice-cold lysis buffer (50mM Tris, pH 7.0, 2.5mM EDTA, with phenylmethylsulfonyl fluoride added just prior use to 0.5MmM from a 0.5M stock in DMSO:ethanol).

Membrane preparation

Cells are pelleted and resuspended in lysis buffer (50 mM Tris, pH 7.0, 2.5 mM EDTA, with PMSF added just prior to use to 0.1 mM from a 0.1 M stock in ethanol), incubated on ice for 15 min, then homogenized with a polytron for 30 sec.

The suspension is spun at 1000g (max) for 10 min at 4°C. The supernatant is saved on ice and the pellets resuspended and spun as before. The supernatants from both spins are combined and spun at 46,000 g(max) for 30 min. The pellets are resuspended in cold Tris buffer (50 mM Tris/Cl, pH 7.0) and spun again. The final pellets are resuspended in membrane buffer (50 mM Tris, 0.32 M sucrose, pH 7.0). Aliquots (1 ml) in polypropylene tubes are frozen in dry ice/ethanol and stored at -70°C until use. The protein concentrations are determined by a modified Lowry assay with sodium dodecyl sulfate.

Binding assays

Membranes are thawed at 37°C, cooled on ice, passed 3 times through a 25-gauge needle, and diluted into binding buffer (50 mM Tris, 3 mM MgCl₂, 1 mg/ml BSA (Sigma A-7888), pH 7.4, which is stored at 4°C after filtration through a 0.22 m filter, and to which has been freshly added 5 μ g/ml aprotinin, 10 μ M bestatin, 10 μ M diprotin A, no DTT). Aliquots of 100 μ l are added to iced 12x75 mm polypropylene tubes containing 100 μ l of the appropriate radioligand and 100 μ l of test compound at various concentrations. Total (TB) and nonspecific (NS) binding are determined in

the absence and presence of 10 μ M naloxone respectively. The tubes are vortexed and incubated at 25°C for 60-75 min, after which time the contents are rapidly vacuum-filtered and washed with about 12 ml/tube iced wash buffer (50 mM Tris, pH 7.0, 3 mM MgCl₂) through GF/B filters (Whatman) presoaked for at least 2h in 0.1% polyethyleneimine. The radioactivity (dpm) retained on the filters is measured with a beta counter after soaking the filters for at least 12h in minivials containing 6-7 ml scintillation fluid. If the assay is set up in 96-place deep well plates, the filtration is over 96-place PEI-soaked unifilters, which are washed with 3 x 1 ml wash buffer, and dried in an oven at 55°C for 2h. The filter plates are counted in a TopCount (Packard) after adding 50 μ l MS-20 scintillation fluid/well.

Functional Assays

The agonist activity of the compounds is measured by determining the degree to which the compounds receptor complex activates the binding of GTP to G-proteins to which the receptors are coupled. In the GTP binding assay, GTP[γ]³⁵S is combined with test compounds and membranes from HEK-293S cells expressing the cloned human opioid receptors or from homogenised rat and mouse brain. Agonists stimulate GTP[γ]³⁵S binding in these membranes. The EC₅₀ and E_{max} values of compounds are determined from dose-response curves. Right shifts of the dose response curve by the delta antagonist naltrindole are performed to verify that agonist activity is mediated through delta receptors. The E_{max} values were determined in relation to the standard δ agonist SNC80, i.e., higher than 100% is a compound that have better efficacy than SNC80.

Procedure for rat brain GTP

Rat brain membranes are thawed at 37°C, passed 3 times through a 25-gauge blunt-end needle and diluted in the GTP γ S binding (50 mM Hepes, 20 mM NaOH, 100 mM NaCl, 1 mM EDTA, 5 mM MgCl₂, pH 7.4, Add fresh: 1 mM DTT, 0.1% BSA). 120 μ M GDP final is added membranes dilutions. The EC₅₀ and E_{max} of compounds are evaluated from 10-point dose-response curves done in 300 μ l with the appropriate amount of membrane protein (20 μ g/well) and 100000-130000 dpm of GTP γ ³⁵S per well (0.11 -0.14nM). The basal and maximal stimulated binding are determined in absence and presence of 3 μ M SNC-80

Data analysis

The specific binding (SB) was calculated as TB-NS, and the SB in the presence of various test compounds was expressed as percentage of control SB.

5 Values of IC_{50} and Hill coefficient (n_H) for ligands in displacing specifically bound radioligand were calculated from logit plots or curve fitting programs such as Ligand, GraphPad Prism, SigmaPlot, or ReceptorFit. Values of K_i were calculated from the Cheng-Prussoff equation. Mean \pm S.E.M. values of IC_{50} , K_i and n_H were reported for ligands tested in at least three displacement curves.

10 Based on the above testing protocols, we find that the compounds of the present invention and some of the intermediates used in the preparation thereof are active toward human δ receptors. Generally, the IC_{50} towards human δ receptor for certain compounds of the present invention is in the range of 0.22 nM – 2.34 nM with an average of 0.98 nM. The EC_{50} and $\%E_{max}$ towards human δ receptor for these compounds are generally in the range of 4.45 nM -155 nM and 62 – 98, respectively.

15 15 The IC_{50} towards human κ and μ receptors for the compounds of the invention is generally in the ranges of 84 nM- 7200 nM and 49 nM – 1800 nM, respectively.

Receptor Saturation Experiments

20 Radioligand K_δ values are determined by performing the binding assays on cell membranes with the appropriate radioligands at concentrations ranging from 0.2 to 5 times the estimated K_δ (up to 10 times if amounts of radioligand required are feasible). The specific radioligand binding is expressed as pmole/mg membrane protein. Values of K_δ and B_{max} from individual experiments are obtained from nonlinear fits of specifically bound (B) vs. nM free (F) radioligand from individual according to a one-site model.

25 Determination Of Mechano-Allodynia Using Von Frey Testing

Testing is performed between 08:00 and 16:00h using the method described by Chaplan et al. (1994). Rats are placed in Plexiglas cages on top of a wire mesh bottom which allows access to the paw, and are left to habituate for 10-15 min. The area tested is the mid-plantar left hind paw, avoiding the less sensitive foot pads. The paw is touched with a series of 8 Von Frey hairs with logarithmically incremental

stiffness (0.41, 0.69, 1.20, 2.04, 3.63, 5.50, 8.51, and 15.14 grams; Stoelting, Ill, USA). The von Frey hair is applied from underneath the mesh floor perpendicular to the plantar surface with sufficient force to cause a slight buckling against the paw, and held for approximately 6-8 seconds. A positive response is noted if the paw is sharply withdrawn. Flinching immediately upon removal of the hair is also considered a positive response. Ambulation is considered an ambiguous response, and in such cases the stimulus is repeated.

Testing Protocol

The animals are tested on postoperative day 1 for the FCA-treated group. The 10 50% withdrawal threshold is determined using the up-down method of Dixon (1980). Testing is started with the 2.04 g hair, in the middle of the series. Stimuli are always presented in a consecutive way, whether ascending or descending. In the absence of a paw withdrawal response to the initially selected hair, a stronger stimulus is presented; in the event of paw withdrawal, the next weaker stimulus is chosen. 15 Optimal threshold calculation by this method requires 6 responses in the immediate vicinity of the 50% threshold, and counting of these 6 responses begins when the first change in response occurs, e.g. the threshold is first crossed. In cases where thresholds fall outside the range of stimuli, values of 15.14 (normal sensitivity) or 0.41 (maximally allodynic) are respectively assigned. The resulting pattern of positive 20 and negative responses is tabulated using the convention, X = no withdrawal; O = withdrawal, and the 50% withdrawal threshold is interpolated using the formula:

$$50\% \text{ g threshold} = 10^{(X_f + k\delta)} / 10,000$$

where X_f = value of the last von Frey hair used (log units); k = tabular value (from Chaplan et al. (1994)) for the pattern of positive / negative responses; and δ = mean 25 difference between stimuli (log units). Here $\delta = 0.224$.

Von Frey thresholds are converted to percent of maximum possible effect (% MPE), according to Chaplan et al. 1994. The following equation is used to compute % MPE:

$$\% \text{ MPE} = \frac{\text{Drug treated threshold (g)} - \text{allodynia threshold (g)}}{\text{Control threshold (g)} - \text{allodynia threshold (g)}} \times 100$$

Administration Of Test Substance

Rats are injected (subcutaneously, intraperitoneally, intravenously or orally) with a test substance prior to von Frey testing, the time between administration of test compound and the von Frey test varies depending upon the nature of the test 5 compound.

Writhing Test

Acetic acid will bring abdominal contractions when administered intraperitoneally in mice. These will then extend their body in a typical pattern. When analgesic drugs are administered, this described movement is less frequently observed 10 and the drug selected as a potential good candidate.

A complete and typical Writhing reflex is considered only when the following elements are present: the animal is not in movement; the lower back is slightly depressed; the plantar aspect of *both* paws is observable. In this assay, compounds of the present invention demonstrate significant inhibition of writhing responses after 15 oral dosing of 1-100 μ mol/kg.

(i) Solutions preparation

Acetic acid (AcOH): 120 μ L of Acetic Acid is added to 19.88 ml of distilled water in order to obtain a final volume of 20 ml with a final concentration of 0.6% AcOH. The solution is then mixed (vortex) and ready for injection.

20 Compound (drug): Each compound is prepared and dissolved in the most suitable vehicle according to standard procedures.

(ii) Solutions administration

The compound (drug) is administered orally, intraperitoneally (i.p.) , subcutaneously (s.c.) or intravenously (i.v.) at 10 ml/kg (considering the average 25 mice body weight) 20, 30 or 40 minutes (according to the class of compound and its characteristics) prior to testing. When the compound is delivered centrally: Intraventricularly (i.c.v.) or intrathecally (i.t.) a volume of 5 μ L is administered.

The AcOH is administered intraperitoneally (i.p.) in two sites at 10 ml/kg (considering the average mice body weight) immediately prior to testing.

30 (iii) Testing

The animal (mouse) is observed for a period of 20 minutes and the number of occasions (Writhing reflex) noted and compiled at the end of the experiment. Mice are kept in individual "shoe box" cages with contact bedding. A total of 4 mice are usually observed at the same time: one control and three doses of drug.

5 For the anxiety and anxiety-like indications, efficacy has been established in the geller-seifter conflict test in the rat.

For the functional gastrointestinal disorder indication, efficacy can be established in the assay described by Coutinho SV *et al*, in American Journal of Physiology - Gastrointestinal & Liver Physiology. 282(2):G307-16, 2002 Feb, in the 10 rat.

ADDITIONAL IN VIVO TESTING PROTOCOLS

Subjects and housing

Naïve male Sprague Dawley rats (175-200g) are housed in groups of 5 in a temperature controlled room (22°C, 40-70% humidity, 12-h light/dark). Experiments 15 are performed during the light phase of the cycle. Animals have food and water ad libitum and are sacrificed immediately after data acquisition.

Sample

Compound (Drug) testing includes groups of rats that do not receive any treatment and others that are treated with *E. coli* lipopolysaccharide(LPS). For the 20 LPS-treated experiment, four groups are injected with LPS, one of the four groups is then vehicle-treated whilst the other three groups are injected with the drug and its vehicle. A second set of experiments are conducted involving five groups of rats; all of which receive no LPS treatment. The naïve group receives no compound (drug) or vehicle; the other four groups are treated with vehicle with or without drug. These are 25 performed to determine anxiolytic or sedative effects of drugs which can contribute to a reduction in USV.

Administration of LPS

Rats are allowed to habituate in the experimental laboratory for 15-20 min prior to treatment. Inflammation is induced by administration of LPS (endotoxin of 30 gram-negative *E. coli* bacteria serotype 0111:B4, Sigma). LPS (2.4μg) is injected

intracerebro-ventricularly (i.c.v.), in a volume of 10 μ l, using standard stereotaxic surgical techniques under isoflurane anaesthesia. The skin between the ears is pushed rostrally and a longitudinal incision of about 1cm is made to expose the skull surface. The puncture site is determined by the coordinates: 0.8 mm posterior to the bregma,

5 1.5 mm lateral (left) to the lambda (sagittal suture), and 5 mm below the surface of the skull (vertical) in the lateral ventricle. LPS is injected via a sterile stainless steel needle (26-G 3/8) of 5 mm long attached to a 100- μ l Hamilton syringe by polyethylene tubing (PE20; 10-15 cm). A 4 mm stopper made from a cut needle (20-G) is placed over and secured to the 26-G needle by silicone glue to create the desired
10 5mm depth.

Following the injection of LPS, the needle remains in place for an additional 10 s to allow diffusion of the compound, then is removed. The incision is closed, and the rat is returned to its original cage and allowed to rest for a minimum of 3.5h prior to testing.

15 **Experimental setup for air-puff stimulation**

The rats remains in the experimental laboratory following LPS injection and compound (drug) administration. At the time of testing all rats are removed and placed outside the laboratory. One rat at a time is brought into the testing laboratory and placed in a clear box (9 x 9 x 18 cm) which is then placed in a sound-attenuating
20 ventilated cubicle measuring 62(w) x35(d) x46(h) cm (BRS/LVE, Div. Tech-Serv Inc). The delivery of air-puffs, through an air output nozzle of 0.32 cm, is controlled by a system (AirStim, San Diego Instruments) capable of delivering puffs of air of fixed duration (0.2 s) and fixed intensity with a frequency of 1 puff per 10s. A maximum of 10 puffs are administered, or until vocalisation starts, which ever comes
25 first. The first air puff marks the start of recording.

Experimental setup for and ultrasound recording

The vocalisations are recorded for 10 minutes using microphones (G.R.A.S. sound and vibrations, Vedbaek, Denmark) placed inside each cubicle and controlled by LMS (LMS CADA-X 3.5B, Data Acquisition Monitor, Troy, Michigan) software.

30 The frequencies between 0 and 32000Hz are recorded, saved and analysed by the

same software (LMS CADA-X 3.5B, Time Data Processing Monitor and UPA (User Programming and Analysis)).

Compounds (Drugs)

5 All compounds (drugs) are pH-adjusted between 6.5 and 7.5 and administered at a volume of 4 ml/kg. Following compound (drug) administration, animals are returned to their original cages until time of testing.

Analysis

10 The recording is run through a series of statistical and Fourier analyses to filter (between 20-24kHz) and to calculate the parameters of interest. The data are expressed as the mean \pm SEM. Statistical significance is assessed using T-test for comparison between naive and LPS-treated rats, and one way ANOVA followed by Dunnett's multiple comparison test (post-hoc) for drug effectiveness. A difference between groups is considered significant with a minimum p value of ≤ 0.05 . Experiments are repeated a minimum of two times.

EXAMPLES

The invention will further be described in more detail by the following Examples which describe methods whereby compounds of the present invention may be prepared, purified, analyzed and biologically tested, and which are not to be construed as limiting the invention.

20 INTERMEDIATE 1: Methyl 4-[(dimethoxyphosphoryl)methyl]benzoate

25 A mixture of 4-(bromomethyl)benzoic acid, methyl ester (11.2 g, 49 mmol) and trimethyl phosphite (25 mL) was refluxed under N₂ for 5 hrs. Excess trimethyl phosphite was removed by co-distillation with toluene to give INTERMEDIATE 1 in quantitative yield. ¹H NMR (CDCl₃) δ 3.20 (d, 2H, J = 22 Hz, CH₂), 3.68 (d, 3H 10.8 Hz, OCH₃), 3.78 (d, 3H, 11.2 Hz, OCH₃), 3.91 (s, 3H, OCH₃), 7.38 (m, 2H, Ar-H), 8.00 (d, 2H, J = 8 Hz, Ar-H).

INTERMEDIATE 2: 4-(4-Methoxycarbonyl-benzylidene)-piperidine-1-carboxylic acid *tert*-butyl ester

30 To a solution of INTERMEDIATE 1 in dry THF (200 mL) was added dropwise lithium diisopropylamide (32.7 mL 1.5 M in hexanes, 49 mmol) at -78 °C.

The reaction mixture was then allowed to warm to room temperature prior to addition of *N*-*tert*-butoxycarbonyl-4-piperidone (9.76 g, 49 mmol in 100 mL dry THF). After 12 hrs, the reaction mixture was quenched with water (300 mL) and extracted with ethyl acetate (3 x 300 mL). The combined organic phases were dried over MgSO₄ and 5 evaporated to give a crude product, which was purified by flash chromatography to provide INTERMEDIATE 2 as a white solid (5.64 g, 35%). IR (NaCl) 3424, 2974, 2855, 1718, 1688, 1606, 1427, 1362, 1276 cm⁻¹; ¹H NMR (CDCl₃) δ 1.44 (s, 9H), 2.31 (t, J = 5.5 Hz, 2H), 2.42 (t, J = 5.5 Hz, 2H), 3.37 (t, J = 5.5 Hz, 2H), 3.48 (t, J = 5.5 Hz, 2H), 3.87 (s, 3H, OCH₃), 6.33 (s, 1H, CH), 7.20 (d J = 6.7 Hz, 2H, Ar-H), 10 7.94 (d, J = 6.7 Hz, 2H, Ar-H); ¹³C NMR (CDCl₃) δ 28.3, 29.2, 36.19, 51.9, 123.7, 127.8, 128.7, 129.4, 140.5, 142.1, 154.6, 166.8.

INTERMEDIATE 3: 4-Bromo-4-[bromo-(4-methoxycarbonyl-phenyl)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester

To a mixture of INTERMEDIATE 2 (5.2 g, 16 mmol) and K₂CO₃ (1.0 g) in 15 dry dichloromethane (200 mL) was added a solution of bromine (2.9 g, 18 mmol) in 30 mL CH₂Cl₂ at 0 °C. after 1.5 hrs at room temperature, the solution after filtration of K₂CO₃ was condensed. The residue was then dissolved in ethyl acetate (200 mL), washed with water (200 mL), 0.5 M HCl (200 mL) and brine (200 mL), and dried over MgSO₄. Removal of solvents provided a crude product, which was 20 recrystallized from methanol to give INTERMEDIATE 3 as a white solid (6.07 g, 78%). IR (NaCl) 3425, 2969, 1725, 1669, 1426, 1365, 1279, 1243 cm⁻¹; ¹H NMR (CDCl₃) δ 1.28 (s, 9H), 1.75 (m, 1H), 1.90 (m, 1H), 2.1 (m, 2H), 3.08 (br, 2H), 3.90 (s, 3H, OCH₃), 4.08 (br, 3H), 7.57 (d, J=8.4 Hz, 2H, Ar-H) 7.98 (d, J=8.4 Hz, 2H, Ar-H); ¹³C NMR (CDCl₃) δ 28.3, 36.6, 38.3, 40.3, 52.1, 63.2, 72.9, 129.0, 130.3, 130.4, 25 141.9, 154.4, 166.3.

INTERMEDIATE 4: 4-[bromo-(4-carboxy-phenyl)-methylene]-piperidine-1-carboxylic acid *tert*-butyl ester


A solution of INTERMEDIATE 3 (5.4 g 11 mmol) in methanol (300 mL) and 2.0 M NaOH (100 mL) was heated at 40 °C for 3 hrs. The solid was collected by 30 filtration, and dried overnight under vacuum. The dry salt was dissolved in 40% acetonitrile/water, and was adjusted to pH 2 using concentrated HCl.

INTERMEDIATE 4 (3.8 g, 87%) was isolated as a white powder by filtration. ¹H NMR (CDCl₃) δ 1.45 (s, 9H, 'Bu), 2.22 (dd, J = 5.5 Hz, 6.1 Hz, 2H), 2.64 (dd, J = 5.5 Hz, 6.1 Hz, 2H), 3.34 (dd, J = 5.5 Hz, 6.1 Hz, 2H), 3.54 (dd, J = 5.5 Hz, 6.1 Hz, 2H), 7.35 (d, J = 6.7 Hz, 2H, Ar-H), 8.08 (d, J = 6.7 Hz, 2H, Ar-H); ¹³C NMR (CDCl₃) δ 5 28.3, 31.5, 34.2, 44.0, 115.3, 128.7, 129.4, 130.2, 137.7, 145.2, 154.6, 170.3.

INTERMEDIATE 5: 4-[bromo-(4-diethylcarbamoyl-phenyl)-methylene]-piperidine-1-carboxylic acid tert-butyl ester

To a solution of INTERMEDIATE 4 (1.0 g, 2.5 mmol) in dry dichloromethane (10 mL) at - 20 °C was added isobutylchloroformate (450 mg, 3.3 mmol). After 20 min at -20 °C diethylamine (4 mL) was added and the reaction was allowed to warm to room temperature. After 1.5 hrs the solvents were evaporated and the residue was partitioned between ethyl acetate and water. The organic phase was washed with brine and dried over MgSO₄. Removal of solvents provided a crude product, which was purified by flash chromatography to give INTERMEDIATE 5 as white needles (800 mg, 73%). IR (NaCl) 3051, 2975, 1694, 1633, 1416, 1281, 1168, 1115 cm⁻¹; ¹H NMR (CDCl₃) δ 1.13 (br, 3H, CH₃), 1.22 (br, 3H, CH₃), 1.44 (s, 9H, 'Bu), 2.22 (t, J = 5.5 Hz, 2H), 2.62 (t, J = 5.5 Hz, 2H), 3.33 (m, 4H), 3.55 (m, 4H), 7.31 (d, J = 8.0 Hz, 2H, Ar-H), 7.36 (d, J = 8.0 Hz, 2H, Ar-H); ¹³C NMR (CDCl₃) δ 12.71, 14.13, 28.3, 31.5, 34.2, 39.1, 43.2, 79.7, 115.9, 126.3, 129.3, 136.8, 137.1, 140.6, 154.6, 170.5.


INTERMEDIATE 6: 4-[bromo[1-phenylmethyl)-4-piperidinylidene]methyl]-N,N-diethylbenzamide



To a solution of INTERMEDIATE 5 (1.0 g, 2.2 mmol) in dichloromethane (15 mL) was added trifluoroacetic acid (2.2 mL, 22.6 mmol). The reaction was stirred

at room temperature overnight and then washed with aqueous sodium hydroxide (1 N). The organic layer was then dried (MgSO_4), filtered and concentrated to give a yellow solid (644 mg, 88%). The yellow solid was dissolved in 1,2-dichloroethane (15 mL) and benzaldehyde (0.32 mL, 3.1 mmol) and sodium triacetoxyborohydride 5 (661 mg, 3.1 mmol) were added. After stirring overnight at room temperature, the reaction was diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate. The aqueous layer was washed with three portions of dichloromethane and the combined organic extracts were dried (MgSO_4), filtered and concentrated. A quantitative amount of INTERMEDIATE 6 was obtained as a yellow foam.


10 **INTERMEDIATE 7: 4-[[4-(acetylamino)phenyl]-4-piperidinylidenemethyl]-N,N-diethyl-benzamide**



To a flask containing INTERMEDIATE 5 (5.04 g, 11.2 mmol) was added toluene (100 mL), ethanol (100 mL), 2.0 M sodium carbonate (35 mL, 70 mmol) and 4'-15 (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)acetanilide (4.39 g, 16.8 mmol). The solution was degassed for 20 minutes and then palladium tetrakis(triphenylphosphine) (1.28 g, 1.06 mmol) was added. The reaction mixture was heated to 90 °C and was stirred overnight under an atmosphere of nitrogen. The reaction mixture was concentrated *in vacuo* and the residue was diluted with ethyl acetate. The solution 20 was washed with two portions of brine and the organic layer was dried (Na_2SO_4), filtered, and concentrated. The residue was purified by flash chromatography, eluting 0% to 100% ethyl acetate in hexanes, to yield the BOC-protected intermediate as a brown solid. The solid was dissolved in dichloromethane (40 mL) and trifluoroacetic acid (10 mL) was added. The reaction was stirred overnight at room temperature. 25 Saturated aqueous sodium bicarbonate was slowly added until bubbling ceased. The layers were separated and the organic layer was washed with one portion of saturated aqueous sodium bicarbonate and then one portion of brine. The organic layer was


dried (Na_2SO_4), filtered and concentrated to give INTERMEDIATE 7 (4.42 g, 98%) as a brown solid. (400 MHz, CDCl_3) δ 1.08-1.18 (m, 3H), 1.19-1.28 (m, 3H), 2.12-2.16 (s, 3H), 2.29-2.41 (m, 5H), 3.23-3.35 (m, 2H), 3.47-3.59 (m, 2H), 7.00 (d, J = 8.40 Hz, 2H), 7.11 (d, J = 8.20 Hz, 2H), 7.29 (d, J = 8.20 Hz, 2H), 7.41 (d, J = 8.59 Hz, 2H).

INTERMEDIATE 8: 4-[(4-aminophenyl)[4-[(diethylamino)carbonyl]phenyl]methylene]-, 1-piperidinecarboxylic acid 1,1-dimethylethyl ester




10 To a solution of INTERMEDIATE 5 (1.00 g, 2.22 mmol) in a mixture of toluene (25 mL) and ethanol (5 mL) was added 4-aminophenylboronic acid hydrochloride (0.578 g, 3.33 mmol) and 2 M Na_2CO_3 (4.40 mL). The solution was degassed with nitrogen for 20 minutes and then tetrakis(triphenylphosphine)palladium (0.256 g, 0.222 mmol) was added. The reaction was heated to 90 °C and stirred for 5 h under an atmosphere of nitrogen. The reaction was cooled to room temperature and the mixture was concentrated. The residue was diluted with ethyl acetate and washed with two portions of brine. The organic layer was dried (Na_2SO_4), filtered and concentrated. The residue was purified by flash chromatography (50% to 80% ethyl acetate in hexanes) to give INTERMEDIATE 8 as a yellow foam (0.68 g, 66%). ^1H NMR (400 MHz, CDCl_3) δ 1.08-1.18 (m, 3H), 1.19-1.29 (m, 3H), 1.47 (s, 9H), 2.26-2.33 (m, 2H), 2.34-2.40 (m, 2H), 3.22-3.36 (m, 2H), 3.40-3.48 (m, 4H), 3.48-3.60 (m, 2H), 6.61 (d, J = 8.20 Hz, 2H), 6.88 (d, J = 8.40 Hz, 2H), 7.12 (d, J = 8.20 Hz, 2H), 7.30 (d, J = 8.20 Hz, 2H).

INTERMEDIATE 9: methyl 4-[{4-[{diethylamino}carbonyl]phenyl}(piperidin-4-ylidene)methyl]phenylcarbamate



Methyl chloroformate (0.13 mL, 1.74 mmol) and zinc dust (0.114 g, 1.74 mmol) were
5 stirred together in dry toluene (10 mL) for 10 minutes. A solution of
INTERMEDIATE 8 (0.805 g, 1.74 mmol) in toluene (10 mL) was cannulated into the
reaction mixture. The reaction was stirred overnight at room temperature under N₂.
The solution was diluted with dichloromethane and washed with saturated aqueous
sodium bicarbonate. The aqueous layer was extracted with two portions of
10 dichloromethane and the combined organic extracts were dried (Na₂SO₄), filtered and
concentrated. The residue was purified by flash chromatography (0% to 50% ethyl
acetate in hexanes). The product was dissolved in dichloromethane (20 mL) and
trifluoroacetic acid (2 mL) was added. The reaction was stirred for two hours at room
temperature. Saturated aqueous sodium bicarbonate was slowly added and then the
15 phases were separated. The aqueous layer was extracted with two portions of
dichloromethane. The combined organic extracts were washed with one portion of
brine, and then dried (Na₂SO₄), filtered and concentrated to give INTERMEDIATE 9
as an off-white solid (0.629 g, 86%). ¹H NMR (400 MHz, CDCl₃) δ 1.08-1.17 (m,
3H), 1.19-1.28 (m, 3H), 2.28-2.36 (m, 4H), 2.86-2.93 (m, 4H), 3.23-3.35 (m, 2H),
20 3.48-3.60 (m, 2H), 3.77 (s, 3H), 7.05 (d, J = 8.59 Hz, 2H), 7.12 (d, J = 8.20 Hz, 2H),
7.28-7.33 (m, 4H).


COMPOUND 1: 4-[(4-aminophenyl)(1-benzylpiperidin-4-ylidene)methyl]-N,N-diethylbenzamide



To a flask containing INTERMEDIATE 6 (0.711 g, 1.61 mmol) was added toluene (25 mL), ethanol (5 mL), 2.0 M sodium carbonate (3.2 mL, 6.4 mmol) and (4-aminophenyl)boronic acid (0.419 g, 2.42 mmol). The solution was degassed for 20 minutes and then palladium tetrakis(triphenylphosphine) (0.189 g, 0.164 mmol) was added. The reaction mixture was heated to 90 °C and was stirred overnight under an atmosphere of nitrogen. The reaction mixture was concentrated *in vacuo* and the residue was diluted with ethyl acetate. The solution was washed with two portions of brine and the organic layer was dried (Na₂SO₄), filtered, and concentrated. The residue was purified by flash chromatography, eluting 0% to 2% methanol in dichloromethane, to yield the product (0.360 g, 49%) as a colourless foam. The compound was dissolved in a 1:5 mixture of dichloromethane/ether (20 mL) and 4.0 mL of 1M HCl in ether was added under an atmosphere of nitrogen. Concentration of the solution provided COMPOUND 1 (418 g, 49%) as its HCl salt. Purity (HPLC) >99%; ¹H NMR (400 MHz, CD₃OD) δ 1.11 (br t, J = 7.03 Hz, 3H), 1.24 (br t, J = 7.03 Hz, 3H), 2.48-2.64 (m, 2H), 3.08-3.22 (m, 2H), 3.22-3.37 (m, 4H), 3.47-3.61 (m, 4H), 4.37 (s, 2H), 7.26 (d, J = 8.40 Hz, 2H), 7.33-7.42 (m, 6H), 7.44-7.60 (m, 5H).


Found: C, 64.45; H, 7.02; N, 7.52. C₃₀H₃₅N₃O x 2.5 HCl x 0.8 H₂O has C, 64.44; H, 7.05; N, 7.51%.

COMPOUND 2: 4-[(4-(acetylamino)phenyl](1-benzylpiperidin-4-ylidene)methyl]-N,N-diethylbenzamide




To a solution of COMPOUND 1 as its hydrochloride salt (0.104 g, 0.198 mmol) and 5 triethylamine (84 μ L, 0.60 mmol) in dichloromethane (10 mL) was added acetic anhydride (20 μ L, 0.21 mmol). The reaction was stirred at room temperature for 20 h under nitrogen. The reaction mixture was washed with saturated aqueous sodium bicarbonate and the layers were separated. The aqueous layer was extracted with three portions of dichloromethane and the combined organic extracts were dried 10 (Na_2SO_4), filtered and concentrated. The residue was purified by reverse phase chromatography, eluting 10% to 45% acetonitrile in water containing 0.1% trifluoroacetic acid. The product was obtained as its TFA salt and was lyophilized to give COMPOUND 2 (0.120 g, 100%) as a colourless solid. Purity (HPLC) >99%; ^1H NMR (400 MHz, CD_3OD) δ 1.12 (br t, J = 7.03 Hz, 3H), 1.23 (br t, J = 7.03 Hz, 3H), 15 2.10 (s, 3H), 2.40-2.54 (m, 2H), 2.69-2.87 (m, 2H), 3.05-3.17 (m, 2H), 3.24-3.34 (m, 2H), 3.47-3.58 (m, 4H), 4.34 (s, 2H), 7.09 (d, J = 8.59 Hz, 2H), 7.24 (d, J = 8.20 Hz, 2H), 7.35 (d, J = 8.40 Hz, 2H), 7.46-7.55 (m, 7H). Found: C, 60.72; H, 5.82; N, 5.96. $\text{C}_{32}\text{H}_{37}\text{N}_3\text{O}_2 \times 1.7 \text{ TFA} \times 0.6 \text{ H}_2\text{O}$ has C, 60.71; H, 5.74; N, 6.00%.

COMPOUND 3: 4-{[4-(acetylamino)phenyl][1-(pyridin-2-ylmethyl)piperidin-4-ylidene]methyl}-N,N-diethylbenzamide




To a solution of INTERMEDIATE 7 (0.549 g, 1.35 mmol) in 1,2-dichloroethane (40 mL) was added 2-pyridinecarboxaldehyde (0.21 mL, 2.2 mmol) and sodium triacetoxyborohydride (0.486 g, 2.29 mmol). The reaction was stirred at room temperature under nitrogen. After 18 hours, the reaction was diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate. The aqueous layer was extracted with two portions of dichloromethane and the combined organic extracts were dried (Na_2SO_4), filtered and concentrated. The residue was purified by reverse phase chromatography, eluting 10% to 45% acetonitrile in water containing 0.1% trifluoroacetic acid. The product was obtained as its TFA salt and was lyophilized to give COMPOUND 3 (0.520 g, 61%) as a yellow solid. Purity (HPLC) >99%; ^1H NMR (400 MHz, CD_3OD) δ 1.12 (br t, J = 7.03 Hz, 3H), 1.23 (br t, J = 6.25 Hz, 3H), 2.10 (s, 3H), 2.65-2.75 (m, 4H), 3.25-3.34 (m, 2H), 3.35-3.46 (m, 4H), 3.48-3.58 (m, 2H), 4.50 (s, 2H), 7.10 (d, J = 8.79 Hz, 2H), 7.25 (d, J = 8.40 Hz, 2H), 7.36 (d, J = 8.40 Hz, 2H), 7.44 (ddd, J = 7.81, 5.08, 1.17 Hz, 1H), 7.47-7.50 (m, 1H), 7.53 (d, J = 8.79 Hz, 2H), 7.90 (td, J = 7.81, 1.76 Hz, 1H), 8.68 (ddd, J = 4.69, 1.56, 0.78 Hz, 1H). Found: C, 55.38; H, 5.11; N, 7.27. $\text{C}_{31}\text{H}_{36}\text{N}_4\text{O} \times 2.4 \text{ CF}_3\text{CO}_2\text{H} \times 0.3 \text{ H}_2\text{O}$ has C, 55.43; H, 5.07; N, 7.22%.

COMPOUND 4: 4-{|4-(acetylamino)phenyl|[1-(pyridin-3-ylmethyl)piperidin-4-ylidene]methyl}-N,N-diethylbenzamide



Using the same method as for COMPOUND 3 and using INTERMEDIATE 7 (0.529 g, 1.30 mmol) and 3-pyridinecarboxaldehyde (0.20 mL, 2.1 mmol) provided COMPOUND 4 (0.477 g, 60%) as a yellow solid. Purity (HPLC): >99%; ¹H NMR (400 MHz, CD₃OD) δ 1.12 (br t, J = 6.64 Hz, 3H), 1.23 (br t, J = 6.83 Hz, 3H), 2.10 (s, 3H), 2.58-2.72 (m, 4H), 3.23-3.45 (m, 6H), 3.49-3.58 (m, 2H), 4.47 (s, 2H), 7.10 (d, J = 8.79 Hz, 2H), 7.24 (d, J = 8.40 Hz, 2H), 7.35 (d, J = 8.40 Hz, 2H), 7.52 (d, J = 8.79 Hz, 2H), 7.68 (dd, J = 7.62, 4.88 Hz, 1H), 8.13-8.17 (m, 1H), 8.71-8.75 (m, 1H), 8.75-8.80 (m, 1H). Found: C, 52.80; H, 4.82; N, 6.75. C₃₁H₃₆N₄O₂ x 2.9 CF₃CO₂H x 0.5 H₂O has C, 52.85; H, 4.81; N, 6.70%.

COMPOUND 5: 4-{|4-(acetylamino)phenyl|[1-(pyridin-4-ylmethyl)piperidin-4-ylidene]methyl}-N,N-diethylbenzamide




Using the same method as for COMPOUND 3 and using INTERMEDIATE 7 (0.516 g, 1.27 mmol) and 4-pyridinecarboxaldehyde (0.20 mL, 2.1 mmol) provided COMPOUND 5 (0.465 g, 60%) as a yellow solid. Purity (HPLC) >97% (215 nm), >97% (254 nm), >99% (280 nm); ¹H NMR (400 MHz, CD₃OD) δ 1.12 (br t, J = 6.64 Hz, 3H), 1.24 (br t, J = 6.83 Hz, 3H), 2.10 (s, 3H), 2.61-2.72 (m, 4H), 3.25-3.41 (m, 6H), 3.47-3.60 (m, 2H), 4.46 (s, 2H), 7.10 (d, J = 8.59 Hz, 2H), 7.24 (d, J = 8.40 Hz,

2H), 7.35 (d, J = 8.40 Hz, 2H), 7.52 (d, J = 8.79 Hz, 2H), 7.74 (d, J = 6.25 Hz, 2H), 8.76 (d, J = 5.86 Hz, 2H). Found: C, 53.24; H, 5.02; N, 6.79. $C_{31}H_{36}N_4O_2 \times 2.7$ $CF_3CO_2H \times 0.9 H_2O$ has C, 53.27; H, 4.97; N, 6.83%.

COMPOUND 6: 4-{{4-(acetylamino)phenyl}[1-(1,2,3-thiadiazol-4-


5 ylmethyl)piperidin-4-ylidene]methyl}-N,N-diethylbenzamide



Using the same method as for COMPOUND 3 and using INTERMEDIATE 7 (0.517 g, 1.27 mmol) and 1,2,3-thiadiazole-4-carbaldehyde (0.232 g, 2.03 mmol) provided COMPOUND 6 (0.435 g, 55%) as a yellow solid. Purity (HPLC) >99%; 1H NMR

10 (400 MHz, CD_3OD) δ 1.13 (br t, J = 6.44 Hz, 3H), 1.23 (br t, J = 7.42 Hz, 3H), 2.10 (s, 3H), 2.37-2.91 (m, 4H), 3.24-3.35 (m, 4H), 3.54-3.72 (m, 4H), 4.91 (s, 2H), 7.10 (d, J = 8.79 Hz, 2H), 7.25 (d, J = 8.40 Hz, 2H), 7.36 (d, J = 8.40 Hz, 2H), 7.53 (d, J = 8.79 Hz, 2H), 9.23 (s, 1H). Found: C, 53.16; H, 5.06; N, 9.83. $C_{28}H_{33}N_5O_2S \times 1.8$ $CF_3CO_2H \times 0.3 H_2O$ has C, 53.13; H, 5.00; N, 9.80%.

15 **COMPOUND 7: 4-{{4-(acetylamino)phenyl}[1-(1,3-thiazol-5-ylmethyl)piperidin-4-ylidene]methyl}-N,N-diethylbenzamide**




Using the same method as for COMPOUND 3 and using INTERMEDIATE 7 (0.401 g, 0.989 mmol) and thiazole-5-carboxaldehyde (0.179 g, 1.58 mmol) provided

20 COMPOUND 7 (0.314 g, 51%) as a pale yellow solid. Purity (HPLC) >96% (215 nm), >96% (254 nm), >99% (280 nm); 1H NMR (400 MHz, CD_3OD) δ 1.12 (br t, J =


6.25 Hz, 3H), 1.23 (br t, J = 6.25 Hz, 3H), 2.10 (s, 3H), 2.36-2.97 (m, 4H), 3.03-3.37 (m, 6H), 3.48-3.62 (m, 2H), 4.68-4.75 (s, 2H), 7.10 (d, J = 8.59 Hz, 2H), 7.24 (d, J = 8.20 Hz, 2H), 7.36 (d, J = 8.01 Hz, 2H), 7.53 (d, J = 8.59 Hz, 2H), 8.09 (s, 1H), 9.20 (s, 1H). Found: C, 52.87; H, 4.99; N, 7.44. $C_{29}H_{34}N_4O_2S \times 2.1 CF_3CO_2H \times 0.7 H_2O$ has C, 52.83; H, 5.01; N, 7.42%.

COMPOUND 8: 4-{{4-(acetylamino)phenyl}[1-(1,3-thiazol-4-ylmethyl)piperidin-4-ylidene]methyl}-N,N-diethylbenzamide



To a solution of INTERMEDIATE 7 (0.399 g, 0.984 mmol) in dry DMF (15 mL) was 10 added potassium carbonate (0.272 g, 1.97 mmol) and 4-chloromethylthiazole hydrochloride (0.251 g, 1.48 mmol). The reaction was stirred overnight under an atmosphere of nitrogen. The reaction mixture was concentrated and the residue was diluted with dichloromethane. The solution was washed with one portion of saturated aqueous sodium bicarbonate. The layers were separated and the aqueous layer was 15 extracted with two portions of dichloromethane. The combined organic extracts were dried (Na_2SO_4), filtered and concentrated. The residue was purified by reverse phase chromatography (gradient 10% to 45% acetonitrile in water containing 0.1% trifluoroacetic acid) to give COMPOUND 8 (0.183 g, 30%) as its TFA salt. The material was lyophilized to produce a colourless solid. Purity (HPLC): >99%; 1H 20 NMR (400 MHz, CD_3OD) δ 1.02 (br t, J = 7.62 Hz, 3H), 1.13 (br t, J = 7.42 Hz, 3H), 2.00 (s, 3H), 2.32-2.79 (m, 4H), 2.98-3.15 (m, 2H), 3.14-3.26 (m, 2H), 3.35-3.59 (m, 4H), 4.43 (s, 2H), 7.00 (d, J = 8.79 Hz, 2H), 7.15 (d, J = 8.40 Hz, 2H), 7.26 (d, J = 8.40 Hz, 2H), 7.43 (d, J = 8.59 Hz, 2H), 7.75 (d, J = 1.76 Hz, 1H), 9.02 (d, J = 1.76 Hz, 1H). Found: C, 55.76; H, 5.10; N, 8.38. $C_{29}H_{34}N_4O_2S \times 1.70 CF_3CO_2H$ has C, 25 55.87; H, 5.17; N, 8.04%.


COMPOUND 9: 4-((1-benzylpiperidin-4-ylidene){4-[(methylsulfonyl)amino]phenyl}methyl)-N,N-diethylbenzamide



To a solution of COMPOUND 1 as its hydrochloride salt (50 mg, 0.095 mmol) and


5 triethylamine (40 μ L, 0.29 mmol) in dichloromethane (5 mL) was added methanesulfonyl chloride (8 μ L, 0.11 mmol). The reaction was stirred at room temperature for 2 days under nitrogen. The mixture was washed with saturated aqueous sodium bicarbonate and the aqueous layer was extracted with two portions of dichloromethane. The combined organic extracts were dried (Na_2SO_4), filtered and 10 concentrated. The residue was purified by reverse phase chromatography (gradient 10% to 45% acetonitrile in water containing 0.1% trifluoroacetic acid) to give COMPOUND 9 (40 mg, 66%) as its TFA salt. The material was lyophilized to produce a colourless solid. Purity (HPLC): >99%; ^1H NMR (400 MHz, CD_3OD) δ 1.12 (t, J = 6.64 Hz, 3H), 1.22 (t, J = 6.83 Hz, 3H), 2.48 (m, 2H), 2.78 (m, 2H), 2.95 (s, 3H), 3.11 (m, 2H), 3.29 (m, 2H), 3.53 (m, 4H), 4.34 (s, 2H), 7.13 (d, J = 8.79 Hz, 2H), 7.20-7.26 (m, 4H), 7.36 (d, J = 8.40 Hz, 2H), 7.50 (s, 5H). Found: C, 56.68; H, 5.61; N, 5.73. $\text{C}_{31}\text{H}_{37}\text{N}_3\text{O}_3\text{S}$ x 1.6 TFA x 0.6 H_2O has C, 56.66; H, 5.53; N, 5.80%.

COMPOUND 10: methyl 4-((1-benzylpiperidin-4-ylidene){4-[(diethylamino)carbonyl]phenyl}methyl)phenylcarbamate



To a solution of INTERMEDIATE 9 (0.398 g, 0.944 mmol) in 1,2-dichloroethane (20 mL) was added benzaldehyde (0.15 mL, 1.5 mmol) and sodium triacetoxyborohydride (0.340 g, 1.60 mmol). The reaction was stirred at room temperature under nitrogen. After 18 hours, the reaction was diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate. The aqueous layer was extracted with two portions of dichloromethane and the combined organic extracts were dried (Na_2SO_4), filtered and concentrated. The residue was purified by reverse phase chromatography, eluting 10% to 50% acetonitrile in water containing 0.1% trifluoroacetic acid. The product was obtained as its TFA salt and was lyophilized to give COMPOUND 10 (0.478 g, 81%) as a colourless solid. Purity (HPLC) >99%; ^1H NMR (400 MHz, CD_3OD) δ 1.12 (br t, J = 7.03 Hz, 3H), 1.23 (br t, J = 6.83 Hz, 3H), 2.41-2.54 (m, 2H), 2.71-2.87 (m, 2H), 3.05-3.16 (m, 2H), 3.25-3.34 (m, 2H), 3.49-3.58 (m, 4H), 3.72 (s, 3H), 4.34 (m, 2H), 7.06 (d, J = 8.79 Hz, 2H), 7.24 (d, J = 8.01 Hz, 2H), 7.35 (d, J = 8.40 Hz, 2H), 7.41 (d, J = 8.40 Hz, 2H), 7.50 (br s, 5H). Found: C, 61.07; H, 5.69; N, 6.04. $\text{C}_{32}\text{H}_{37}\text{N}_3\text{O}_2 \times 1.7 \text{ CF}_3\text{CO}_2\text{H} \times 0.4 \text{ H}_2\text{O}$ has C, 61.03; H, 5.71; N, 6.04%.


COMPOUND 11: 4-{{[4-(acetylamino)phenyl][1-(2-fluorobenzyl)piperidin-4-ylidene]methyl}-N,N-diethylbenzamide



To a solution of INTERMEDIATE 7 as the TFA salt (0.300 g, 0.58 mmol) in 1,2-dichloroethane (20 mL) was added 2-fluorobenzaldehyde (0.12 mL, 1.14 mmol) and sodium triacetoxyborohydride (0.307 g, 1.45 mmol). The reaction was stirred at room temperature under nitrogen. After 18 hours, the reaction was quenched with water, diluted with dichloromethane and filtered through Celite. The filtrate was concentrated and the residue purified by reverse phase chromatography, eluting 5% to 80% acetonitrile in water containing 0.1% trifluoroacetic acid. The product was


obtained as its TFA salt and was lyophilized to give COMPOUND 11 (0.182 g, 50%) as a white solid. Purity (HPLC) >99%; ¹H NMR (400 MHz, CD₃OD) δ 1.12 (t, J = 6.93 Hz, 3H), 1.23 (t, J = 6.74 Hz, 3H), 2.10 (s, 3 H), 2.41-2.63 (m, 2H), 2.69-2.94 (m, 2H), 3.10-3.24 (m, 2H), 3.24-3.37 (m, 2H), 3.47-3.65 (m, 4H), 4.43 (s, 2H), 7.10 5 (ddd, J = 8.93, 2.34, 2.20 Hz, 2H), 7.22-7.27 (m, 2H), 7.27-7.38 (m, 4H), 7.50-7.54 (m, 2H), 7.54-7.60 (m, 2H). Found: C, 61.43; H, 5.34; N, 6.51. C₃₂H₃₆N₃O₂F x 1.5 CF₃CO₂H has C, 61.40; H, 5.52; N, 6.14%.

10 **COMPOUND 12: 4-{|4-(acetylamino)phenyl|[1-(3-fluorobenzyl)piperidin-4-ylidene|methyl}-N,N-diethylbenzamide**



Using the same method as for COMPOUND 11 and using INTERMEDIATE 7 as the TFA salt (0.308 g, 0.77 mmol) and 3-fluorobenzaldehyde (0.16 mL, 1.52 mmol) provided COMPOUND 12 (0.237 g, 58%) as a white solid. Purity (HPLC) >99%; ¹H NMR (400 MHz, CD₃OD) δ 1.12 (t, J = 6.54 Hz, 3H), 1.23 (t, J = 6.74 Hz, 3H), 2.10 15 (s, 3H), 2.41-2.56 (m, 2H), 2.72-2.89 (m, 2H), 3.07-3.20 (m, 2H), 3.25-3.34 (m, 2H), 3.48-3.59 (m, 4H), 4.36 (s, 2H), 7.10 (ddd, J = 8.84, 2.44, 2.20 Hz, 2H), 7.20-7.38 (m, 9H), 7.49-7.57 (m, 2H). Found: C, 62.17; H, 5.52; N, 6.36. C₃₂H₃₆N₃O₂F x 1.4 CF₃CO₂H has C, 62.08; H, 5.60; N, 6.24%.


COMPOUND 13: 4-{{[4-(acetylamino)phenyl][1-(4-fluorobenzyl)piperidin-4-ylidene]methyl}-N,N-diethylbenzamide



Using the same method as for COMPOUND 11 and using INTERMEDIATE 7 as the
 5 TFA salt (0.300 g, 0.58 mmol) and 4-fluorobenzaldehyde (0.12 mL, 1.14 mmol)
 provided COMPOUND 13 (0.151 g, 42%) as a white solid. Purity (HPLC) >99%; ¹H
 NMR (400 MHz, CD₃OD) δ 1.12 (t, J = 6.93 Hz, 3H), 1.23 (t, J = 7.03 Hz, 3H), 2.10
 (s, 3H), 2.41-2.54 (m, 2H), 2.72-2.89 (m, 2H), 3.04-3.17 (m, 2H), 3.25-3.34 (m, 2H),
 3.48-3.60 (m, 4H), 4.34 (s, 2H), 7.09 (ddd, J = 8.84, 2.44, 2.20 Hz, 2H), 7.20-7.27 (m,
 10 4H), 7.35 (dt, J = 8.10, 1.61 Hz, 2H), 7.50-7.58 (m, 4H). Found: C, 60.07; H, 5.42;
 N, 6.00. C₃₂H₃₆N₃O₂F x 1.7 CF₃CO₂H has C, 60.10; H, 5.37; N, 5.94%.

What is claimed is :

1. A compound of formula I, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:



5

wherein

R^1 is selected from C_{6-10} aryl and C_{2-6} heteroaryl, wherein said C_{6-10} aryl and C_{2-6} heteroaryl are optionally substituted with one or more groups selected from -R, $-NO_2$, -OR, -Cl, -Br, -I, -F, $-CF_3$, $-C(=O)R$, $-C(=O)OH$, $-NH_2$, -SH, -NHR, $-NR_2$, -SR, $-SO_3H$, $-SO_2R$, $-S(=O)R$, -CN, -OH, $-C(=O)OR$, $-C(=O)NR_2$, $-NRC(=O)R$, and $-NRC(=O)-OR$, wherein R is, independently, a hydrogen or C_{1-6} alkyl;

R^2 is selected from C_{1-3} alkyl and hydrogen; and

R^3 is selected from hydrogen, $-C(=O)-R^4$, $-S(=O)_2-R^4$, and $-C(=O)-O-R^4$, 15 wherein R^4 is selected from -H, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl.

2. A compound according to claim 1,

wherein R^1 is selected from phenyl; thiadiazolyl, pyridyl; thienyl; furyl; imidazolyl; triazolyl; pyrrolyl; thiazolyl; and N-oxido-pyridyl, wherein said R^1 is further optionally substituted with one or more groups selected from C_{1-6} alkyl, 20 halogenated C_{1-6} alkyl, $-NO_2$, $-CF_3$, C_{1-6} alkoxy, chloro, fluoro, bromo, and iodo;

R^2 is selected from C_{1-3} alkyl and hydrogen; and

R^3 is selected from hydrogen, $-C(=O)-R^4$, $-S(=O)_2-R^4$, and $-C(=O)-O-R^4$, wherein R^4 is C_{1-6} alkyl.

3. A compound according to claim 1,
wherein R¹ is selected from phenyl; pyridyl; thiadiazolyl and thiazolyl,
wherein R¹ is further optionally substituted with one or more groups selected from C₁-
6alkyl, halogenated C₁₋₆alkyl, -NO₂, -CF₃, C₁₋₆ alkoxy, chloro, fluoro, bromo, and
5 iodo;

R² is hydrogen; and
R³ is selected from hydrogen, -C(=O)-R⁴, -S(=O)₂-R⁴, and -C(=O)-O-R⁴,
wherein R⁴ is C₁₋₃alkyl.

10 4. A compound according to claim 1, wherein
wherein R¹ is selected from phenyl; 2-fluorophenyl; 3-fluorophenyl; 4-
fluorophenyl; 2-pyridyl; 3-pyridyl; 4-pyridyl; 1,2,3-thiadiazol-4-yl; 4-thiazolyl and 5-
thiazolyl;
R² is hydrogen; and
15 R³ is selected from hydrogen, -C(=O)-CH₃, -S(=O)₂-CH₃, and -C(=O)-O-CH₃.

5. A compound according to claim 1, wherein the compound is selected from:
4-[(4-aminophenyl)(1-benzylpiperidin-4-ylidene)methyl]-N,N-diethylbenzamide;
4-[[4-(acetylamino)phenyl](1-benzylpiperidin-4-ylidene)methyl]-N,N-
20 diethylbenzamide;
4-{{[4-(acetylamino)phenyl][1-(pyridin-2-ylmethyl)piperidin-4-ylidene]methyl}-N,N-
diethylbenzamide;
4-{{[4-(acetylamino)phenyl][1-(pyridin-3-ylmethyl)piperidin-4-ylidene]methyl}-N,N-
diethylbenzamide;
25 4-{{[4-(acetylamino)phenyl][1-(pyridin-4-ylmethyl)piperidin-4-ylidene]methyl}-N,N-
diethylbenzamide;
4-{{[4-(acetylamino)phenyl][1-(1,2,3-thiadiazol-4-ylmethyl)piperidin-4-
30 ylidene]methyl}-N,N-diethylbenzamide;
4-{{[4-(acetylamino)phenyl][1-(1,3-thiazol-5-ylmethyl)piperidin-4-ylidene]methyl}-
N,N-diethylbenzamide;
4-{{[4-(acetylamino)phenyl][1-(1,3-thiazol-4-ylmethyl)piperidin-4-ylidene]methyl}-
N,N-diethylbenzamide;

4-((1-benzylpiperidin-4-ylidene){4-[(methylsulfonyl)amino]phenyl}methyl)-*N,N*-diethylbenzamide;

methyl 4-((1-benzylpiperidin-4-ylidene){4-[(diethylamino)carbonyl]phenyl}methyl)phenylcarbamate;

5 4-{{4-(acetylamino)phenyl}[1-(2-fluorobenzyl)piperidin-4-ylidene]methyl}-*N,N*-diethylbenzamide;

4-{{4-(acetylamino)phenyl}[1-(3-fluorobenzyl)piperidin-4-ylidene]methyl}-*N,N*-diethylbenzamide;

4-{{4-(acetylamino)phenyl}[1-(4-fluorobenzyl)piperidin-4-ylidene]methyl}-*N,N*-

10 diethylbenzamide;

and pharmaceutically acceptable salts thereof.

6. A compound according to any one of claims 1-5 for use as a medicament.

15 7. The use of a compound according to any one of claims 1-5 in the manufacture of a medicament for the therapy of pain, anxiety or functional gastrointestinal disorders.

8. A pharmaceutical composition comprising a compound according to any one 20 of claims 1-5 and a pharmaceutically acceptable carrier.

9. A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-5.


25

10. A method for the therapy of functional gastrointestinal disorders in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-5.


30

11. A process for preparing a compound of formula I, comprising:

48



reacting a compound of formula II with X-R³ or R³-O-R³:



5

wherein X is halogen;


R¹ is selected from C₆₋₁₀aryl and C₂₋₆heteroaryl, wherein said C₆₋₁₀aryl and C₂₋₆heteroaryl are optionally substituted with one or more groups selected from -R, -NO₂, -OR, -Cl, -Br, -I, -F, -CF₃, -C(=O)R, -C(=O)OH, -NH₂, -SH, -NHR, -NR₂, -SR, -SO₃H, -SO₂R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR₂, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or C₁₋₆alkyl;

R² is selected from C₁₋₃alkyl and hydrogen; and


R³ is selected from -C(=O)-R⁴, -S(=O)₂-R⁴, and -C(=O)-O-R⁴, wherein R⁴ is selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl and C₂₋₆alkynyl.

12. A process for preparing a compound of formula I, comprising:

49



reacting a compound of formula III with R¹-CHO:



5

III

wherein R¹ is selected from C₆₋₁₀aryl and C₂₋₆heteroaryl, wherein said C₆₋₁₀aryl and C₂₋₆heteroaryl are optionally substituted with one or more groups selected from -R, -NO₂, -OR, -Cl, -Br, -I, -F, -CF₃, -C(=O)R, -C(=O)OH, -NH₂, -SH, -NHR, -NR₂, -SR, -SO₃H, -SO₂R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR₂, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or C₁₋₆alkyl;


R² is selected from C₁₋₃alkyl and hydrogen; and

R³ is selected from -C(=O)-R⁴, -S(=O)₂-R⁴, and -C(=O)-O-R⁴, wherein R⁴ is selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl and C₂₋₆alkynyl.

15


13. A process for preparing a compound of formula I, comprising:

50



reacting a compound of formula IV with a compound of formula V or esters thereof:

5




wherein R¹ is selected from C₆₋₁₀aryl and C₂₋₆heteroaryl, wherein said C₆₋₁₀aryl and C₂₋₆heteroaryl are optionally substituted with one or more groups selected from -R, -NO₂, -OR, -Cl, -Br, -I, -F, -CF₃, -C(=O)R, -C(=O)OH, -NH₂, -SH, -NHR, -NR₂, -SR, -SO₃H, -SO₂R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR₂, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or C₁₋₆alkyl;

R^2 is selected from C_{1-3} alkyl and hydrogen; and

R^3 is selected from $-H$, $-C(=O)-R^4$, $-S(=O)_2-R^4$, and $-C(=O)-O-R^4$, wherein R^4

15 is selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl and C₂₋₆alkynyl.

14. A compound of formula VI, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:



VI

5 wherein R² is selected from C₁₋₃alkyl and hydrogen;
R³ is selected from hydrogen, -C(=O)-R⁴, -S(=O)₂-R⁴, and -C(=O)-O-R⁴,
wherein R⁴ is selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl and C₂₋₆alkynyl; and
R⁵ is selected from hydrogen and -C(=O)-O-C₁₋₆alkyl.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2005/000013

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 211/70, A61K 31/445, A61P 25/04, A61P 25/22
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02094812 A1 (ASTRAZENECA AB), 28 November 2002 (28.11.2002) --	1-14
X	WO 9828275 A1 (ASTRA PHARMA INC. ET AL), 2 July 1998 (02.07.1998) -----	1-14

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier application or patent but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

29 April 2005

02-05-2005

Name and mailing address of the ISA/
 Swedish Patent Office
 Box 5055, S-102 42 STOCKHOLM
 Facsimile No. +46 8 666 02 86

Authorized officer
 Solveig Gustavsson/ELY
 Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No. _____

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 9 - 10

because they relate to subject matter not required to be searched by this Authority, namely:

Claims 9-10 relate to a method of treatment of the human or animal body by surgery or by therapy, as well as diagnostic

... / ...

2. Claims Nos.:

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

Box II.1

methods /Rule 39.1(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds.

INTERNATIONAL SEARCH REPORT

Information on patent family members

01/04/2005

International application No.

PCT/SE 2005/000013

WO	02094812	A1	28/11/2002	AU	8040501	A	25/02/2002
				BG	108326	A	30/12/2004
				BR	0209676	A	27/07/2004
				CA	2446332	A	28/11/2002
				CN	1509282	A	30/06/2004
				CZ	20033085	A	12/05/2004
				EE	200300540	A	16/02/2004
				EP	1395576	A	10/03/2004
				HU	0401096	A	28/09/2004
				IL	158704	D	00/00/0000
				MX	PA03010439	A	09/03/2004
				NO	20035116	D	00/00/0000
				SE	0101765	D	00/00/0000
				SK	13952003	A	06/04/2004
				US	20040142967	A	22/07/2004

WO	9828275	A1	02/07/1998	AU	737999	B	06/09/2001
				AU	5351298	A	17/07/1998
				BR	9714055	A	09/05/2000
				CA	2274074	A	02/07/1998
				CN	1146540	C	21/04/2004
				CN	1246111	A	01/03/2000
				CZ	9902199	A	17/11/1999
				EE	3824	B	15/08/2002
				EE	9900256	A	15/12/1999
				EP	0946511	A	06/10/1999
				ID	22074	A	00/00/0000
				IL	130535	D	00/00/0000
				JP	2001507350	T	05/06/2001
				NO	313670	B	11/11/2002
				NO	993022	A	20/08/1999
				NZ	336029	A	30/03/2001
				PL	334374	A	28/02/2000
				RU	2193029	C	20/11/2002
				SE	9604785	D	00/00/0000
				SK	76299	A	08/11/1999
				SK	283211	B	04/03/2003
				TR	9901417	T	00/00/0000
				TW	548271	B	00/00/0000
				US	6187792	B	13/02/2001
				US	6455545	B	24/09/2002
				US	6693117	B	17/02/2004
				US	20010021715	A	13/09/2001
				US	20030149023	A	07/08/2003
				US	20040171612	A	02/09/2004
				ZA	9711059	A	22/06/1998
				HU	0000610	A	28/09/2000
				SE	9702535	D	00/00/0000